This article is more than 5 years old. Information may no longer be current.

IOP elevation more frequent in younger patients after intravitreal triamcinolone acetonide

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal injection of triamcinolone acetonide causes more frequent IOP elevation in younger patients, according to a study by researchers in India. "Other aspects of IOP response and its treatment were similar to older patients," the study authors said.

Dhananjay Shukla, MD, and colleagues reviewed IOP outcomes for 164 eyes of 164 patients aged 21 to 80 years after intravitreal injection of 4 mg/0.1 mL of triamcinolone acetonide. Fifty-one patients presented with exudative age-related maculopathy, and 113 patients presented with macular edema, according to the study.

The mean baseline IOP for all patients was 15.07 mm Hg, the authors noted.

After injection, the mean rise in IOP was 6.6 mm Hg. IOP was greater than 21 mm Hg in 42 patients (25.6%), the authors reported.

Specifically, IOP rose in 14 (45%) of the 31 patients aged 45 years or younger, compared with 28 (21%) of the 133 patients over 45 years of age (P = .006).

"The groups were similar in baseline IOP, IOP rise, mean time-lag to maximum IOP and response to treatment," the authors said.

The study is published in the September issue of American Journal of Ophthalmology.